EW stock: buy or sell?

EW stock price: $227.46 -0.15% At close on October 18th, 2019

Updated on:
October 18th, 2019

4

Edwards Lifesciences stayed stable -0.15% on Oct 18th to $227.46 after topping to all time highs on October/11.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally.

Should I buy EW stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Edwards Lifesciences stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Edwards Lifesciences stock a buy?

Financial institutions and banks publish stock ratings everyday. At Stocks2.com, we gathered 15 ratings published for EW stock in the last month.

The general sentiment of these ratings is bullish for EW stock, with 12 positive ratings.
Is EW a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-6Wells Fargo & Con/aOutperform
2019-9-23Piper Jaffray Companiesn/aOverweight
2019-7-25BTIG Researchn/aHold
2019-7-24Wells Fargo & Con/aOutperform
2019-7-24Raymond Jamesn/aOutperform
2019-7-24Raymond Jamesn/aOutperform
2019-7-24Morgan Stanleyn/aOverweight
2019-7-24JPMorgan Chase & Co.n/aNeutral
2019-7-24Jefferies Financial Groupn/aBuy
2019-7-24Credit Suisse Groupn/aOutperform
2019-7-24Canaccord Genuityn/aBuy
2019-7-24BMO Capital Marketsn/aOutperform
2019-7-24Barclaysn/aUnderweight
2019-7-24Bank of AmericaBuyBuy
2019-7-16Morgan Stanleyn/aOverweight

EW stock analysis

Daily outlook

Edwards Lifesciences stayed steady -0.15% to $227.46 after marking all time highs on October/11.

Edwards Lifesciences stayed constant -0.15% on Oct 18th to $227.46 after marking all time highs on Oct 11th. Since SMA50d and SMA100d crossed up on July, EW price climbed $36.28 per share (18.98%). On Oct 11th, EW hit new all time highs, pushing higher previous ATH of $229.97 recorded on Oct 4th. New ATHs are usual entry points for many trading setups as there aren't higher resistences. Since price and SMA100d lines crossed up on June, EW climbed $53.42 (30.69%).

EW stock chart (daily)

Weekly outlook

Edwards Lifesciences shares stayed steady 0.15% this week, ending at $227.46. Late September EW rocketed a cool 5.28% in just one week.

Edwards Lifesciences stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Not so far away is the last all-time high Edwards Lifesciences marked last week. Late December 2018 EW price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

EW stock chart (weekly)

EW stock price history

EW stock went public on March 27th, 2000 with a price of $3.811. Since then, EW stock grew a 5,870.10%, with a yearly average of 309.00%. If you had invested $1,000 in EW stock in 2000, it would worth $58,701.00 today.

1: Adjusted price after possible price splits or reverse-splits.

EW stock historical price chart

EW stock reached all-time highs on October 11th with a price of $230.19.

EW stock price target is $227.30

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 14 price predictions for EW stock:
EW stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-6Wells Fargo & CoRaises Target$220.00$250.0013.6%
2019-9-23Piper Jaffray CompaniesInitiatesn/a$240.00-
2019-7-24Wells Fargo & CoReiterates$207.00$220.006.3%
2019-7-24Raymond JamesReiterates$200.00$232.0016%
2019-7-24Raymond JamesRaises Target$200.00$232.0016%
2019-7-24Morgan StanleyRaises Target$210.00$228.008.6%
2019-7-24JPMorgan Chase & Co.Raises Target$190.00$225.0018.4%
2019-7-24Jefferies Financial GroupReiterates$210.00$245.0016.7%
2019-7-24Credit Suisse GroupReiterates$221.00$226.002.3%
2019-7-24Canaccord GenuityReiterates$215.00$250.0016.3%
2019-7-24BMO Capital MarketsReiterates$204.00$224.009.8%
2019-7-24BarclaysRaises Target$160.00$175.009.4%
2019-7-24Bank of AmericaReiterates$215.00$225.004.7%
2019-7-16Morgan StanleyRaises Target$197.00$210.006.6%
(in average)$203.80$227.3012.0%
Moving in a range from $250.00 and $175.00, the price prediction for EW stock is $227.30. In average, analysts' outlook on EW price target is positive, increasing the prediction by a 12.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report on April, Edwards Lifesciences . Unfortunately, reported EPS is not yet available in our database.
EW earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a1.03n/a
2017-Q32017-10-240.860.84-2.3%
2017-Q42018-02-010.910.943.3%
2018-Q12018-04-241.11.2210.9%
2018-Q22018-07-261.131.249.7%
2018-Q32018-10-231.011.075.9%
2018-Q42019-01-311.171.170.0%
2019-Q12019-04-221.23n/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

In 2018, Edwards Lifesciences annual turnover rose a great 8.37% to $3,722.80 million dollars from $3,435.30 marked in 2017. In contrast, its profit margin (compared to revenues) inched to 19.40%, that is $722.20 million.

To have an updated view of the financial situation of Edwards Lifesciences, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Edwards Lifesciences TTM sales up to March 2019 were $3,821.00 and earnings were $765.30 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Edwards Lifesciences business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, appreciated a tiny 2.64%. Regarding profit margin, Edwards Lifesciences remained stable 0.63% to 19.40%

EW annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$2,050 M-$392 M19.1%-
2014$2,323 M13.31%$811 M34.9%107.07%
2015$2,494 M7.35%$495 M19.8%-38.98%
2016$2,964 M18.85%$570 M19.2%15.07%
2017$3,435 M15.91%$584 M17.0%2.48%
2018$3,723 M8.37%$722 M19.4%23.75%
TTM $3,821 M2.64%$765 M20.0%5.97%

Quarterly financial results

Edwards Lifesciences posted $993.00 M in revenues for 2019-Q1, a 1.56% up compared to previous quarter. Reported quarter income marked $249.70 M with a profit margin of 25.15%. Profit margin skyrocketed a 24.43% compared to previous quarter when profit margin was 0.72%. When comparing turnover to same quarter last year, Edwards Lifesciences sales marked a superb increase and rocketed a 10.97%. Looking back to recent quarterly results, Edwards Lifesciences posted 2 negative quarters in a row.
EW quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$842 M-$186 M22.1%-
2017-Q3$822 M-2.41%$170 M20.7%-8.60%
2017-Q4$889 M8.16%$-3 M-0.3%-101.65%
2018-Q1$895 M0.71%$207 M23.1%-7,478.57%
2018-Q2$944 M5.46%$283 M30.0%36.83%
2018-Q3$907 M-3.93%$226 M24.9%-20.09%
2018-Q4$978 M7.84%$7 M0.7%-96.90%
2019-Q1$993 M1.56%$250 M25.1%3,467.14%

Edwards Lifesciences ownership

When you are planning to buy shares of a company, it's worth to have a look its ownership structure.

Edwards Lifesciences shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 3.94% of all shares.

In case of Edwards Lifesciences stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EW stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Edwards Lifesciences:

EWBSXCRYICUILMAT
Market cap$47.3 B$53.5 B$888.0 M$3.2 B$695.7 M
Total shares208.0 M1,390.0 M37.5 M20.7 M19.9 M
Float shares206.5 M1,390.0 M36.0 M19.2 M16.1 M
  - Institutional holdings (%)0.0%93.4%72.1%93.5%77.8%
  - Insider holdings (%)3.9%0.2%3.8%7.1%18.5%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

EW summary

Friday, October 18th, 2019
Open$227.36
Close$227.46
Day range$227.29 - $229.67
Previous close$227.80
Session gain-0.15%
Average true range$5.17
50d mov avg$220.31
100d mov avg$206.69
200d mov avg$191.04
Daily pattern
Weekly pattern lt06a

Edwards Lifesciences performance

To better understand Edwards Lifesciences performance you must becnhmark its gains with other related stocks in same sector or industry. For Edwards Lifesciences, the comparison is made against Boston Scientific, CryoLife, ICU Medical, LeMaitre Vascular, Medtronic and Merit Medical Systems.
Stock3m6m12m
EWEdwards Lifescien...17.05%28.32%56.42%
BSXBoston Scientific-8.95%9.57%5.28%
CRYCryoLife-21.25%-14.05%-25.98%
ICUIICU Medical-38.11%-29.78%-41.16%
LMATLeMaitre Vascular15.52%29.43%26.35%
MDTMedtronic7.81%29.73%17.61%
MMSIMerit Medical Sys...-44.31%-46.86%-51.15%

Edwards Lifesciences competitors

We selected a few stocks to conform a list of Edwards Lifesciences competitors to watch if you are interested in investing in EW:

Latest EW stock news